1292 / 1674
Conclusion MA17R: extended AI
•
Possible option for N+ BC+
•
4% benefit in DFS, 0% in OS
•
Mainly secondary prevention
•
Reduction of metastatic risk: 1.1%
•
Risk-benefit ratio to be determined
|
|
1292 / 1674
1292 / 1674
Conclusion MA17R: extended AI
•
Possible option for N+ BC+
•
4% benefit in DFS, 0% in OS
•
Mainly secondary prevention
•
Reduction of metastatic risk: 1.1%
•
Risk-benefit ratio to be determined